Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CSL : Behring to Present New Real-World Data on Outcomes Following Acute Coronary Syndrome at American Heart Association Scientific Sessions 2020

11/11/2020 | 08:41am EST

Global biotherapeutics leader CSL Behring today announced that results of two separate analyses will be shared at this year's American Heart Association (AHA) Scientific Sessions 2020, being held virtually from November 13-17.

The data include real-world data from a U.S. Medicare claims database on the clinical and economic impact of major adverse cardiovascular events (MACE) and rehospitalizations in the 90-day, high-risk period following an acute myocardial infarction (MI). CSL Behring will also host a Learning Studio session with Drs. Deepak Bhatt and Peter Libby of Brigham and Women's Hospital to discuss cholesterol efflux, an emerging target area for novel therapies.

'Our research on cardiovascular disease and its impact on public health includes real-world studies on cardiovascular care and our ongoing Phase 3 AEGIS-II trial of CSL112, a novel therapy being investigated to improve outcomes in heart attack survivors,' said Larry Deckelbaum, Vice President, Research and Development, Cardiovascular and Metabolic Therapeutic Area at CSL Behring. 'We are excited to be a part of the AHA Scientific Sessions and share new findings from this research which include important real-world insights on the 90-day high-risk period that follows a heart attack.'

Learning Studio session: Improving Early Outcomes for the Post-AMI Patient: Cholesterol Efflux and the Role of ApoA-I in Plaque Stabilization

Includes presentations by Dr. Deepak L. Bhatt, executive director of Interventional Cardiovascular Programs and Dr. Peter Libby, cardiovascular medicine specialist, both of Brigham and Women's Hospital and Harvard Medical School

About CSL112

CSL112, Apolipoprotein A-I (Human), is a novel formulation of human plasma-derived apoA-I, the primary functional component of high-density lipoproteins (HDL). Studies have shown that an infusion of CSL112 rapidly enhances cholesterol efflux capacity. Cholesterol efflux is the first and most critical step in reverse cholesterol transport and is the body's primary mechanism for clearing cells of excess cholesterol that would otherwise continue to accumulate in plaque. This build-up of plaque over time can rupture and potentially cause a cardiovascular event. Compared to the standard of care, CSL112 is a therapy that may offer a unique approach to reduce the risk of cardiovascular death, myocardial infarction (MI), and stroke in acute coronary syndrome (ACS) patients diagnosed with either STEMI or NSTEMI.

About cardiovascular disease

Cardiovascular disease is the leading cause of death globally, with an estimated 800,000 acute MIs occurring each year in the U.S. alone.1,2 Patients who survive a heart attack are at high risk of experiencing early recurrent CV events. The majority of these 1-year recurrent CV events (approximately 60%) occur in the first 90 days after the index event.3 Although the overall rate of MIs has decreased over the last two to three decades,4 the proportion of the events occurring in the first 90 days remains unchanged.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, the company develops and delivers innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 27,000 people worldwide, and delivers its life-saving therapies to people in more than 100 countries.

World Health Organization. Cardiovascular diseases (CVDs) - Fact Sheet. 2017.

Benjamin E, et al. American Heart Association. Heart Disease and Stroke Statistics-2018 Update. Circulation. 2018;137:e1-e442.

Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.

Szummer K, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J. 2017; 38:3056-3065.

Media Contact:

Natalie de Vane

Tel: 610-999-8756

Email: Natalie.deVane@cslbehring.com

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about CSL LIMITED
05:54aCSL : Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Commun..
AQ
01/21Australian shares on track to gain 1.5% for week on further U.S. stimulus hop..
RE
01/18Australia shares jump 1% on reports Queensland to lift lockdown curbs
RE
01/12Australia blocks Chinese buyout of builder over security concerns -media
RE
01/11Gold miners drag down Australian shares; NZ falls 2%
RE
01/08Australia shares notch best week in 2 months on broader global rally
RE
01/07MARKET CHATTER : CSL to Finish Production of First Batch of AstraZeneca COVID-19..
MT
01/06Australian shares end 1% lower as U.S. runoff results trickle in
RE
01/05Australia shares open lower as domestic virus concerns weigh
RE
2020Australia shares dip on Sydney restrictions, NZ inches down
RE
More news
Financials (USD)
Sales 2021 10 121 M - -
Net income 2021 2 254 M - -
Net Debt 2021 4 668 M - -
P/E ratio 2021 43,0x
Yield 2021 1,02%
Capitalization 96 714 M 97 068 M -
EV / Sales 2021 10,0x
EV / Sales 2022 9,29x
Nbr of Employees 27 000
Free-Float 100,0%
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | CSL | AU000000CSL8 | MarketScreener
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 229,21 $
Last Close Price 212,57 $
Spread / Highest target 18,1%
Spread / Average Target 7,83%
Spread / Lowest Target -8,20%
EPS Revisions
Managers and Directors
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Brian Anthony McNamee Chairman
Paul McKenzie Chief Operating Officer
Joy Carolyn Linton Chief Financial Officer
Andrew Cuthbertson Chief Scientific Officer & Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED-2.70%96 486
SAMSUNG BIOLOGICS CO.,LTD.-4.36%47 370
BIOGEN INC.12.53%42 401
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.12.91%41 235
ALEXION PHARMACEUTICALS, INC.2.23%35 304
CELLTRION HEALTHCARE CO LTD--.--%21 154